J.P. Morgan discloses dealings in Kangji Medical privatization

The Executive received a disclosure of securities dealings from J.P. Morgan Securities PLC on October 22, 2025, in relation to the privatization of Kangji Medical Holdings Limited by way of scheme of arrangement. These dealings were made pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers.

J.P. Morgan Securities PLC, identified as a Class (5) associate connected with the Offeror and ultimately owned by JPMorgan Chase & Co., conducted several "closing out of a derivative contract" transactions for its own account. These transactions involved derivatives referencing Kangji Medical shares. The maturity/closing out date for all reported derivatives is December 29, 2025.

Specific transactions included closing out derivatives relating to 525 reference securities for a total of $4,721.43, 16,500 reference securities for $148,387.80, and 3,000 reference securities for $26,979.60. All these derivative contracts were closed out at a reference price of $8.9932 per security. Following these dealings, the resultant balance for J.P. Morgan Securities PLC stands at 10,418,336 shares.